COVID19 Archives - Dermatology Advisor

Practice Management

IL-6 Inhibitors Associated With Reduced In-Hospital COVID-19 Mortality

By

Bradley van Paridon

January 21, 2021

Investigators assessed whether interleukin-6 inhibitors reduced the odds of in-hospital COVID-related mortality.

General Dermatology

“COVID-19 Toe” and Underrepresentation in People of Color: Is Racial Bias to Blame?

By

Brandon May

January 20, 2021

The association of COVID-19 and chilblains in patients with skin of color was evaluated.

Practice Management

Higher Mortality Seen in Younger Patients With COVID-19 vs Influenza

By

Virginia A. Schad, PharmD, RPh

January 20, 2021

Mortality is higher in younger patients with COVID-19 compared with younger patients with influenza.

Practice Management

Pfizer-BioNTech COVID-19 Vaccine Elicits Response Against Key Mutation

By

Diana Ernst, RPh

January 19, 2021

The study was conducted by Pfizer and the University of Texas Medical Branch.

Practice Management

Allergists Affirm Safety of COVID-19 Vaccines for Most

January 19, 2021

In a special article, reassurance is provided regarding potential allergic reactions to mRNA COVID-19 vaccinations.

Practice Management

For Some Americans, the COVID-19 Pandemic Shifted Perceptions About Poverty

By

Jessica Nye

January 15, 2021

The researchers tested whether the COVID-19 pandemic has altered beliefs about the extent to which poverty is caused by external forces and internal dispositions and support for economic inequality.

Practice Management

SARS-CoV-2 Seroprevalence and Risk Factors Among Close Contacts

By

Bradley van Paridon

January 14, 2021

Intensive health surveillance of close contracts of patients with COVID-19 provided a rare opportunity to determine asymptomatic attack rates and SARS-CoV-2 transmission risk factors.

Practice Management

Rapid Decay of IgA and IgM Following COVID-19 Infection

By

Jessica Nye

January 12, 2021

Study authors measured the levels of immunoglobulin M, IgG, and IgA in healthcare workers, and observed fast decay of 2 antibodies which has implications for further seroprevalence studies.

Practice Management

False Results Possible With Curative SARS-CoV-2 Test, Says FDA

By

Brian Park, PharmD

January 11, 2021

The test should be utilized in accordance with its Emergency Use Authorization and as described in the authorized labeling to reduce the risk of false negative results.

Practice Management

Case Series Describes Use of Icosapent Ethyl for COVID-19 Pneumonia

By

Cassandra Pardini, PharmD

January 8, 2021

The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.